Wolverine legal status still leaves pharmacy permission unanswered
Can your pharmacy make the blend? FDA hasn't clarified permission after requests to assess the ingredients were taken back from its safety-risk Category 2 process.
The July meeting hasn't settled your pharmacy question
Did the July talks allow pharmacies to use the blend? No published FDA decision settles that question for you.
BPC-157 and TB-500 were discussed on July 23-24, 2026 [13]. FDA staff argued against allowing either ingredient.
FDA's list covers raw ingredients used to make medicines. You may hear these called bulk ingredients.
FDA hasn't published what follows from the meeting. An advisory group advises; FDA must separately change the rules [12][13].
A July 2026 discussion isn't permission for your medicine. The talks didn't test the blend's safety for you.
The numbered pharmacy rules below need a short explanation. Rule 503A covers pharmacies preparing medicine for one patient's prescription.
Other registered medicine makers prepare larger batches. Both still have to follow rules about allowed ingredients.
FDA's safety group covers ingredients it considers risky. Requests to assess these ingredients were taken back.
Taking back a request doesn't grant drug approval. You still need a clear answer about pharmacy permission.
FDA lists withdrawn requests without clearing pharmacy use
On FDA's page current April 22, 2026, both nominations were withdrawn, so the two Wolverine components are no longer in the Category 2 table; FDA has not answered whether a 503A pharmacy may compound either one. This is the present-tense fact. The limit that still stands is a separate one: a 503A pharmacy may work only from eligible ingredients, and neither peptide is on the 503A bulks list.
That restriction does not convert a catalog listing into an approval signal: Promise Peptides clinicians may prescribe Wolverine (research blend) through mypromise.com after an evaluation by a licensed clinician, but the availability of prescription care does not alter the FDA status recorded below.
The U.S. Federal Food, Drug, and Cosmetic Act governs compounding through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [11]. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; otherwise the substance must be nominated and evaluated by FDA [11].
Under FDA's interim policy, Category 2 bulk drug substances are those nominated with sufficient information to evaluate but that FDA has identified as raising significant safety risks. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder for compounding with a Category 2 substance [11]. FDA placed both components there in 2023 for the same documented reasons.
- BPC-157 was identified by FDA as a bulk drug substance that may present significant safety risks and placed in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [10].
- TB-500 is listed by FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the thymosin beta-4 fragment that is the TB-500 channel of this blend — and was likewise placed in Category 2, effective with the September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information [10].
Neither component is an FDA-approved drug, and the blend has no approved therapeutic indication [10]. FDA staff proposed against listing both BPC-157 and TB-500 before the July 23-24, 2026 PCAC meeting; as of September 2026, the agency had published no record of the committee's votes [10][13].
Your prescription doesn't override the ingredient rules
How can a pharmacy prepare medicine to fit your needs? Your care starts with a health check by a U.S. licensed prescriber.
Your prescriber checks whether a medicine made specially fits you. A lawful, suitable medicine also needs your own prescription.
A 503A pharmacy is state-licensed and makes medicine for a named patient [11]. That's the kind described by the numbered pharmacy rule above.
A 503B facility is a registered maker preparing larger batches under FDA oversight [11]. These are different from pharmacies making one patient's prescription.
You can have the health visit in person or by video. Either way, your prescriber needs the proper license.
Video care still needs a real health check and prescription [11]. The video visit doesn't change the allowed ingredients.
Your prescription alone can't make an ingredient lawful to use. The pharmacy must also follow the ingredient rules.
FDA placed both Wolverine ingredients in its safety-risk group, Category 2 [11]. Ingredients in that group lacked temporary permission for routine pharmacy use.
People withdrew their requests for FDA to assess the ingredients. That means the requests were taken back, rather than approved.
FDA hasn't answered the question of present pharmacy permission. You still need that answer alongside your own health assessment.
The general rules don't establish a treatment for your knee. Neither a prescription nor a video visit settles ingredient permission.
Your care provider can address your own health needs. These pages don't name a pharmacy or give treatment instructions.
Sports rules ban both substances during and between events
Your sport may prohibit the substances even between events. Drug rules for relevant sports come from the World Anti-Doping Agency [9].
BPC-157 falls under its ban on unapproved substances. TB-500 and thymosin beta-4 also face sports bans.
Your pharmacy question and your sports rules are separate. Permission to make medicine wouldn't cancel a sports ban.
Taking back the requests hasn't settled Wolverine access.
People had asked FDA to consider allowing BPC-157 and TB-500 as ingredients. Those requests were taken back, rather than approved [10].
The ingredients left the safety-risk group called Category 2. You're still waiting for FDA to clarify pharmacy permission.
Neither BPC-157 nor TB-500 has FDA treatment approval [9][10]. WADA bans the substances in sport.
FDA discussed them for its ingredient list on July 23-24, 2026. Staff opposed adding them; published votes were absent by September 2026 [13].
BPC-157 still lacks a clear pharmacy answer.
The BPC-157 request was taken back, and Category 2 no longer lists the ingredient. FDA hasn't explained whether a patient's pharmacy may prepare it [10][11].
You need a licensed prescriber's assessment and your own prescription. Your medicine's maker also needs permission for that ingredient [11].
BPC-157 isn't on FDA's list for making medicines from raw ingredients. Those rules are separate from the old safety-risk grouping.
The ingredient appeared on the July 2026 agenda. FDA staff argued against allowing the ingredient [13].
Each Wolverine ingredient has to meet FDA rules.
The mix doesn't have separate permission under the ingredient rules. Both parts entered Category 2, FDA's safety-risk group.
FDA listed that status in its September 29, 2023 update. Its page current as of April 22, 2026 lists the requests as withdrawn [10].
Ingredients in Category 2 lacked temporary permission for routine pharmacy use. FDA hasn't said how that policy treats requests taken back [11].
BPC-157 and TB-500 were discussed on July 23-24, 2026. FDA hadn't published meeting votes by September 2026 [13].
Missing FDA approval doesn't change the sports bans.
You don't have an FDA-approved treatment purpose for the pair. Neither substance has approval for treating people.
In September 2023, FDA placed BPC-157 and the thymosin beta-4 piece TB-500 in Category 2. That group meant serious safety concerns.
FDA's page current as of April 22, 2026 lists requests taken back [10]. You can still read FDA's concerns about safety there.
FDA's answer about preparing medicine still hasn't been given. Taking back a request doesn't establish BPC-157 safety.
WADA still bans BPC-157 under its unapproved-substance rules [9]. TB-500 and thymosin beta-4 also remain prohibited in sport.